碘西他酸 | 16034-77-8

• 物质功能分类: 原料药 - 诊断用药 - 影象检查用药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 碘西他酸
• 中文别名: 3-(N-(3-氨基-2,4,6-三碘苯基)乙酰氨基)-2-甲基丙酸
• 英文名称: iocetamic acid
• 英文别名: N-(3-amino-2,4,6-triiodophenyl)-3-acetamido-2-methyl-propionic acid；jocetamic acid；locetamic acid；cholimil；N-Acetyl-N-(3-amino-2,4,6-triiod-phenyl)-β-aminoisobuttersaeure, Iocetamsaeure；3-(N-acetyl-3-amino-2,4,6-triiodoanilino)-2-methylpropanoic acid
• CAS: 16034-77-8
• 化学式: C₁₂H₁₃I₃N₂O₃
• 分子量: 613.96
• InChiKey: GSVQIUGOUKJHRC-UHFFFAOYSA-N

物化性质

• 熔点：
  224-225° (NL 6515305); mp range 191-212° (Korver); Consists of 2 isomers having mps 232° and 200-201°
• 沸点：
  658.2±55.0 °C(Predicted)
• 密度：
  2.2000 (rough estimate)
• 颜色/状态：
  WHITE TO LIGHT CREAM-COLORED POWDER
• 气味：
  ODORLESS OR HAS FAINT ACETIC ACID ODOR
• 溶解度：
  PRACTICALLY INSOL IN WATER; SOMEWHAT SOL IN ETHER, BENZENE; SLIGHTLY SOL IN ACETONE, CHLOROFORM
• 稳定性/保质期：

  UNSTABLE IN LIGHT

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

ADMET

代谢

与肝脏中的葡萄糖醛酸结合...

...CONJUGATED WITH GLUCURONIC ACID IN LIVER...

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

用于GI钡餐检查的媒体和口服给药可能引起恶心、呕吐和腹泻。急性肾小管坏死被认为是摄入某些胆囊染料的后果。/碘化对比剂/

MEDIA USED FOR GI ROENTGENOGRAPHY & AGENTS ADMIN ORALLY MAY CAUSE NAUSEA, VOMITING, & DIARRHEA. ACUTE TUBULAR NECROSIS HAS BEEN REPORTED TO BE THE CONSEQUENCE OF INGESTION OF CERTAIN GALLBLADDER DYES. /IODINATED CONTRAST MEDIA/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

在2,200例使用碘克酸进行的检查中，报告了4例严重的皮肤反应。尽管皮肤反应的发生率仅为1.8%，但其严重性导致了使用另一种药剂进行口服胆囊造影。

OUT OF 2,200 EXAM WITH IOCETAMIC ACID, 4 CASES OF SEVERE SKIN REACTIONS WERE REPORTED. EVEN THOUGH INCIDENCE OF SKIN REACTIONS WAS 1.8%, ITS SEVERITY INDUCED THE USE OF ANOTHER AGENT FOR ORAL CHOLECYSTOGRAPHY.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

急性碘中毒可能在给药后立即或数小时后发生。血管性水肿是突出的症状，喉部肿胀可能导致窒息。可能出现多处皮肤出血。还可能表现出类似血清病型超敏反应的症状，如发热、关节痛、淋巴结肿大和嗜酸性粒细胞增多。已经有过因对碘超敏反应而导致的血栓性血小板减少性紫癜和致命的结节性多动脉炎的描述。/碘制剂/

ONSET OF ACUTE IODIDE POISONING MAY OCCUR IMMEDIATELY OR SEVERAL HR AFTER ADMIN. ANGIOEDEMA IS OUTSTANDING SYMPTOM, & SWELLING OF LARYNX MAY LEAD TO SUFFOCATION. MULTIPLE CUTANEOUS HEMORRHAGES MAY BE PRESENT. ALSO MANIFESTATIONS OF SERUM-SICKNESS TYPE HYPERSENSITIVITY, SUCH AS FEVER, ARTHRALGIA, LYMPH NODE ENLARGEMENT, & EOSINOPHILIA, MAY APPEAR. THROMBOTIC THROMBOCYTOPENIC PURPURA & FATAL PERIARTERITIS NODOSA ATTRIBUTED TO HYPERSENSITIVITY TO IODIDE HAS BEEN DESCRIBED. /IODINE PREPN/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

第一例严重血小板减少症发生在一个成年男性摄入广泛使用的胆道造影剂碘克酸后。

THE FIRST CASE OF SEVERE THROMBOCYTOPENIA OCCURRED IN AN ADULT MALE AFTER INGESTION OF A WIDELY USED CHOLECYSTOGRAPHIC MEDIUM, IOCETAMIC ACID.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

口服后迅速吸收，在肝脏与葡萄糖醛酸结合，以不透射线的葡萄糖醛酸苷形式分泌到胆汁中，并在功能正常的胆囊中浓缩。

...RAPIDLY ABSORBED FOLLOWING ORAL ADMIN, CONJUGATED WITH GLUCURONIC ACID IN LIVER, SECRETED INTO BILE AS RADIOPAQUE GLUCURONIDE, & CONCN IN THE FUNCTIONING GALL BLADDER.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 海关编码：
  2924299090

制备方法与用途

胆盐水(DRC 1201)是一种诊断辅助剂，是一种口服活性造影剂。

文献信息

• GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS
  申请人：South Dakota Board of Regents

  公开号：US20200048305A1

  公开（公告）日：2020-02-13

  The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.

  本发明描述了含有胆固醇-连接剂-谷胱甘肽共轭物的组合物，通过克服血脑屏障（BBB）进入中枢神经系统的屏障入口，包括这些组合物的胶束和脂质体形式。此外，还公开了通过给予这些组合物治疗受试者的方法。
• Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
  申请人：Bezwada Rao S.

  公开号：US20120035259A1

  公开（公告）日：2012-02-09

  The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

  本发明提供了一氧化氮(NO)和可选的药物释放的大分子和寡聚物，其中药物分子和一氧化氮释放部分通过可吸收的大分子或可水解降解的寡聚物链连接，并且大分子或寡聚物由来自诸如乙醇酸、乳酸、己内酰胺和对二恶烷等安全且生物相容的分子的重复单元组成。此外，本发明还涉及从一氧化氮和/或药物分子释放的大分子或寡聚物控制释放一氧化氮(NO)。此外，本发明还涉及包含本发明的一氧化氮和药物释放大分子和寡聚物的医疗器械、医疗器械涂层和治疗方法。
• ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES
  申请人：Bezwada Biomedical, LLC

  公开号：US20140142199A1

  公开（公告）日：2014-05-22

  The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile.

  本发明涉及一种新型可水解异氰酸酯、可水解支链多元醇及其制备的支链可吸收聚酯和聚氨酯的发现。由此得到的可吸收聚合物可用于药物输送、支架、高孔隙率泡沫、网状泡沫、组织工程、组织粘合剂、防止粘连、骨蜡制剂、医疗设备涂层、表面改性剂以及其他可植入医疗设备。此外，这些可吸收聚合物可以具有受控的水解降解特性。
• Functionalized drugs and polymers derived therefrom
  申请人：Bezwada S. Rao

  公开号：US20060172983A1

  公开（公告）日：2006-08-03

  Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.

  从中选择的化合物：其中DRUG-OH，DRUG-COOH和DRUG-NH2是生物活性化合物；每个X独立地从— COO—（乙二酸基团），—CH(CH3)COO—（乳酸基团），— O COO—（二氧杂环己酮基团），— COO—（己内酯基团），—(CH2)yCOO—中选择，其中y为2-4或6-24和—( O)z COO—，其中z为2-24；每个Y独立地从—CO O—（乙二酸酯基团），—COCH( )O—（乳酸酯基团），—CO O O—（二氧杂环己酮酯基团），—CO O—（己内酯酯基团），—CO( )mO—，其中m为2-4或6-24和—CO O( O)n—，其中n为2-24；R′为氢，苄基或烷基，烷基可以是直链或支链；p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。